SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines

The severe acute respiratory syndrome coronavirus 2 variant JN.1 recently emerged as the dominant variant despite having only one amino acid change on the spike (S) protein receptor binding domain (RBD) compared with the ancestral BA.2.86, which never represented more than 5% of global variants. To define at the molecular level the JN.1 ability to spread globally, we interrogated a panel of 899 neutralizing human monoclonal antibodies. Our data show that the single leucine-455-to-serine mutation in the JN.1 spike protein RBD unleashed the global spread of JN.1, likely occurring by elimination of more than 70% of the neutralizing antibodies mediated by IGHV3-53/3-66 germlines. However, the resilience of class 3 antibodies with low neutralization potency but strong Fc functions may explain the absence of JN.1 severe disease.

Authors

Institutions

Publication Details

Journal
Science Immunology
Published
2024-08-09
DOI
https://doi.org/10.1126/sciimmunol.adp9279
Citations
19
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
7.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines

Giulio Pierleoni, Emanuele Andreano, Giulia Realini, Maria Grazia Cusi et al.
19 citations
Science Immunology
SARS-CoV-2 and COVID-19 Research
7.39
article

SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines

Giulio Pierleoni, Emanuele Andreano, Giulia Realini, Maria Grazia Cusi, Marco Troisi, Giuseppe Maccari, Ida Paciello, Rino Rappuoli, Gabriele Anichini, Federica Perrone
article en
19 citations

Abstract

The severe acute respiratory syndrome coronavirus 2 variant JN.1 recently emerged as the dominant variant despite having only one amino acid change on the spike (S) protein receptor binding domain (RBD) compared with the ancestral BA.2.86, which never represented more than 5% of global variants. To define at the molecular level the JN.1 ability to spread globally, we interrogated a panel of 899 neutralizing human monoclonal antibodies. Our data show that the single leucine-455-to-serine mutation in the JN.1 spike protein RBD unleashed the global spread of JN.1, likely occurring by elimination of more than 70% of the neutralizing antibodies mediated by IGHV3-53/3-66 germlines. However, the resilience of class 3 antibodies with low neutralization potency but strong Fc functions may explain the absence of JN.1 severe disease.

Science ImmunologyVol. 9(98)
University of Siena (IT), Toscana Life Sciences (IT)
Good health and well-being
Openalex Percentile: Top 2%
SARS-CoV-2 and COVID-19 Research
7.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.